Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Antibody & Cellular Immune responses in children after 2 vs 3 doses and pre vs post booster of PCV13 Vaccine

Award Number: R03HD088909
ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/13/2017
PERIOD OF PERFORMANCE END DATE: 06/30/2019

Group Awards By:

View Award Description

Antibody & Cellular Immune responses in children after 2 vs 3 doses and pre vs post booster of PCV13 Vaccine - Abstract: The recent World Health Organization policy statement on pneumococcal conjugate vaccines (PCVs) endorsed a schedule of 3 primary doses without a booster (3p+0 schedule) or, as a new alternative, 2 primary doses with a booster dose (2p+1 schedule) considering the cost for low- income countries. PCV13 was licensed in the U.S. for 3 primary doses plus a booster (3p+1 schedule) supported by high efficacy demonstrated by 2 large scales US-based clinical trials. A clear understanding of the full impact of reduced-dose schedules of PCV on protective antibody levels and functionality as well as induction of immunologic B- and T- cell memory is lacking. This study will determine specific immune responses of children receiving 2 primary doses, 3 primary doses and 3p+1 doses of PCV13 and provide for the first time direct comparison of IgG antibody levels, functional antibody differences and cellular immune memory differences in the same cohort of children. Clinically relevant significant differences in levels of antibodies, functional antibodies, and memory B-cell and CD4+ T-cell responses can be measured after 2 compared to 3 primary doses of PCV13 and a booster dose in the second year of life that stimulates clinically relevant increases in antibodies, memory B-cell and CD4+ T-cell responses. We will explore this hypothesis by comparing immune responses in prospectively collected blood samples from infants after 2p vs. 3p doses of PCV13 and pre vs. post booster PCV13. Prospectively collected blood samples of children at 4 time points after PCV13 doses will be analyzed to quantitate differences in immune responses. Healthy children aged 6-18 months from Rochester, NY, USA will have samples of plasma and immune cells studied after PCV13 doses. The study will provide a novel assessment of antibody levels and functionality as well as B- and T-cell memory immune responses against all PCV13 serotypes following 2p vs. 3p doses and pre vs. post booster doses in children. Remarkably few studies have looked at the antibody responses against all 13 polysaccharides in one cohort of children and none have simultaneously focused on examination of B- and T-cell specific memory. The findings will strengthen or bring to question policy decisions impacting children worldwide regarding recommendations for PCV administration schedules. Understanding the impact of each dose of PCV13 to generate replenished memory B-cell pool and T helper cells will provide valuable information to assess any changes in immunization schedules.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2020 ( Subtotal = -$3,668 )
2020	2018	ROCHESTER GENERAL HOSPITAL, THE	1425 PORTLAND AVE	ROCHESTER	NY	14621	MONROE	USA	Child Health and Human Development Extramural Research	000	2	1/10/2020	NON-COMPETING CONTINUATION	-$3,668
														Subtotal = -$3,668

Issue Date FY: 2018 ( Subtotal = $85,043 )
2018	2018	ROCHESTER GENERAL HOSPITAL, THE	1425 PORTLAND AVE	ROCHESTER	NY	14621	MONROE	USA	Child Health and Human Development Extramural Research	000	2	6/26/2018	NON-COMPETING CONTINUATION	$85,043
														Subtotal = $85,043

Issue Date FY: 2017 ( Subtotal = $84,828 )
2017	2017	ROCHESTER GENERAL HOSPITAL, THE	1425 PORTLAND AVE	ROCHESTER	NY	14621	MONROE	USA	Child Health and Human Development Extramural Research	000	1	7/13/2017	NEW	$84,828
														Subtotal = $84,828

Grand Total All Awards = $166,203

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Antibody & Cellular Immune responses in children after 2 vs 3 doses and pre vs post booster of PCV13 Vaccine

Award Number: R03HD088909

ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/13/2017

PERIOD OF PERFORMANCE END DATE: 06/30/2019

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer